Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection.

[1]  P. Patel,et al.  Association of standing-order policies with vaccination rates in dialysis clinics: a US-based cross-sectional study. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  A. Eslamifar,et al.  Efficacy and long‐term immunogenicity of hepatitis B vaccine in haemodialysis patients , 2009, International journal of clinical practice.

[3]  A. Moorman,et al.  Nonhospital Health CareAssociated Hepatitis B and C Virus Transmission: United States, 19982008 , 2009, Annals of Internal Medicine.

[4]  C. Gutierrez,et al.  Evaluación a largo plazo de la respuesta inmunológica a la vacuna de la hepatitis B en 136 pacientes en hemodiálisis , 2009 .

[5]  I. Tsouchnikas,et al.  Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. , 2007, Clinical Nephrology.

[6]  M. Alter,et al.  A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States , 2006, Pediatrics.

[7]  S. Seirafian,et al.  Response Rate to Hepatitis B Vaccination in Patients with Chronic Renal Failure and End-Stage-Renal-Disease: Influence of Diabetes Mellitus , 2005 .

[8]  M. Alter,et al.  Special Article: National Surveillance of Dialysis‐Associated Diseases in the United States, 2002 , 2005, Seminars in dialysis.

[9]  C. Galli,et al.  Reduced protection against hepatitis B virus following vaccination in patients with Type 1 (insulin-dependent) diabetes , 1987, Diabetologia.

[10]  Jerome I. Tokars,et al.  Recommendations for preventing transmission of infections among chronic hemodialysis patients , 2001 .

[11]  S. Sezer,et al.  Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. , 2000, Transplantation proceedings.

[12]  M. Alter,et al.  Protective effect of hepatitis B vaccine in chronic hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  H. Margolis,et al.  Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. , 1998, American journal of preventive medicine.

[14]  F. Locatelli,et al.  Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  P. Goldwater.  Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders , 1997 .

[16]  R. Peces,et al.  Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  M. Haubitz,et al.  Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. , 1996, Clinical Nephrology.

[18]  R. Marcén,et al.  Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. , 1996, American journal of nephrology.

[19]  D. Marcelli,et al.  Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. , 1996, Nephron.

[20]  R. Rault,et al.  Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. , 1995, ASAIO journal.

[21]  L. Grillner,et al.  Nosocomial spread of hepatitis B virus (HBV) in a haemodialysis unit confirmed by HBV DNA sequencing. , 1995, The Journal of hospital infection.

[22]  M. Buti,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. , 1992, American journal of nephrology.

[23]  S. Hadler,et al.  Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. , 1991, The Journal of infectious diseases.

[24]  F. André.  Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. , 1989, The American journal of medicine.

[25]  E. Scolnick,et al.  Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. , 1986, The Journal of infection.

[26]  D. de Zeeuw,et al.  Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. , 1985, Nephron.

[27]  W. Szmuness,et al.  Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. , 1984, The New England journal of medicine.

[28]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .